Genzyme Corporate Research Search Genzyme Websites
Information for Fabry Disease patients and their familiesFabry disease treatment information for health care professionals
Fabrazyme This website is intended for use in the United States. Please visit the Genzyme website for your country or region.
Patients and Families
About Fabry Disease
About Fabrazyme
Fabrazyme Facts
Clinical Studies
How It's Made
Treatment
Support and Resources
Product Information
Genzyme Fabrazyme

Fabrazyme Facts

What is Fabrazyme?

Fabrazyme ® (agalsidase beta) is a medication designed to replace the alpha-GAL enzyme, which is missing or insufficient in people with Fabry disease. This type of medication is known as an enzyme replacement therapy (or ERT).

How Does it Work?

People with Fabry disease are missing or have insufficient amounts of the alpha-GAL enzyme. Without enough of this enzyme, a fatty substance called globotriaosylceramide (GL-3) builds up in the cells throughout the body.

Fabrazyme is intended to replace the alpha-GAL enzyme, which breaks down accumulated GL-3. Treatment with Fabrazyme every two weeks may improve the signs and symptoms of Fabry disease, since Fabrazyme has been shown to reduce GL-3 levels in certain cells. The relationship between GL-3 reduction and the improvement of specific signs and symptoms, however, has not been established.

How is Fabrazyme Treatment Given?

Fabrazyme is given by intravenous (IV) infusion, meaning that the medication is infused directly into your bloodstream through a vein. Fabrazyme cannot be taken orally as a pill or liquid because it is an enzyme that would be destroyed in your digestive system. Infusion into the bloodstream bypasses your body’s digestive processes and allows Fabrazyme to go to work in cells throughout the body.

What is the Recommended Dosage?

The recommended dosage of Fabrazyme is 1.0 milligram (mg) for each kilogram (kg) of body weight given once every 2 weeks as an IV infusion. For instance, a man weighing 70 kg (approximately 154 pounds) would receive 70 mg of Fabrazyme.

What are the Possible Side Effects of Fabrazyme?

The most serious and common side effects reported with Fabrazyme are infusion reactions, meaning that they occurred as a result of the infusion. Infusion reactions occurred in many people treated with Fabrazyme, and some of the reactions were severe. Side effects may include: increase in heart rate, increase in blood pressure up to a few hours after infusion, throat tightness, chest pain/tightness, shortness of breath, fever, chills, abdominal pain, itching, hives, nausea, vomiting, lip or ear swelling, rash, decrease in blood pressure, muscle pain and headache.

To reduce the potential for an infusion reaction, your health care provider will give you anti-fever medications (for example, acetaminophen or ibuprofen) before the infusion. Infusion reactions occurred in some people after receiving anti-fever medications, antihistamines, and oral steroids.


Important Safety Information

Fabrazyme (agalsidase beta) is indicated for use in patients with Fabry disease.  Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types. The reduction of GL-3 inclusions suggests that Fabrazyme may ameliorate disease expression; however, the relationship of GL-3 inclusion reduction to specific clinical manifestations of Fabry disease has not been established.

The most serious and most common adverse reactions reported with Fabrazyme are infusion reactions.  Serious and/or frequently occurring related adverse reactions consisted of one or more of the following events: chills, pyrexia, feeling hot or cold, dyspnea, nausea, flushing, headache, vomiting, paresthesia, fatigue, pruritus, pain in extremity, hypertension, chest pain, throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion, diarrhea, edema peripheral, myalgia, back pain, pallor, bradycardia, urticaria, hypotension, face edema, rash, and somnolence. The occurrence of somnolence can be attributed to clinical trial specified pre-treatment with antihistamines. 
 
Other reported serious adverse events included stroke, pain, ataxia, bradycardia, cardiac arrhythmia, cardiac arrest, decreased cardiac output, vertigo, hypoacousia, and nephrotic syndrome.  These adverse events also occur as manifestations of Fabry disease; an alteration in frequency or severity cannot be determined from the small numbers of patients studied.

Infusion reactions occurred in many patients treated with Fabrazyme and some of the reactions were severe.  Patients should be given antipyretics prior to infusion.  Infusion reactions occurred in some patients after receiving pretreatment with antipyretics, antihistamines, and oral steroids.  Infusion reactions declined in frequency with continued use of Fabrazyme.  However, infusion reactions may still occur despite extended duration of Fabrazyme treatment.  Because of the potential for severe infusion reactions, appropriate medical support measures should be readily available when Fabrazyme is administered. 

Patients with compromised cardiac function should be monitored closely if the decision is made to administer Fabrazyme.

Most patients develop IgG antibodies to Fabrazyme.  A few patients developed IgE or skin test reactivity specific to Fabrazyme.  Physicians should consider testing for IgE in patients who experienced suspected allergic reactions and consider the risks and benefits of continued treatment in patients with anti- Fabrazyme IgE.   Patients with Fabrazyme- specific IgE antibody have been treated using a rechallenge protocol.  Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

The safety and efficacy in patients younger than 8 years of age have not been evaluated.  IgE immunologic responses in pediatric patients may differ from those in adults, as IgG seroconversion was associated with prolonged half-life concentrations of Fabrazyme, which is rarely observed in adult patients.

Fabrazyme is available by prescription only. Side effects should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn more, please see the full prescribing information (PDF) or contact Genzyme at 1-800-745-4447.
 
Keyword: 
Search In: 
Resources

Insurance and Reimbursement
Information Request
Ask Us
Learn About the Fabry Registry
Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142
617 768 9000
800 745 4447
Contact Us
 
This website is intended for use in the United States. Please visit the Genzyme website for your country or region.



Terms and Conditions of Use | Privacy Policy | © 2003-2008 Genzyme Corporation. All rights reserved. |  Fabr/US/P133/02/07 |  Site Map
Genzyme Therapeutics